Project Grant R43NS077735

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $335,410 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Vaxess Technologies, Inc. for the "Development of a Needle Free Microarray Patch for Delivery of a GLP-1 Receptor Agonist". The project aims to explore the use of Vaxess' MIMIX platform, a novel microneedle array patch (MAP) technology, to enable simple and effective delivery of...

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $284,517 Project Grant (CFDA 93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research) to Electronic Biosciences, Inc. to develop a point-of-care diagnostic assay for detecting autoantibodies associated with type 1 diabetes (T1D). This project aims to leverage nanopore technology to create a rapid, cost-effective test for screening populations, especially children, for T1D biomarkers that appear...

The General Hospital Corporation (MGH) Research Management Division was awarded a $458,585 Project Grant from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to develop a method for detecting autoantibodies against beta-amyloid in serum as a potential biomarker for Alzheimer's disease (AD). The 2-year project aims to investigate the use of small molecule compounds called CRANAD-XS to differentially tune the binding between beta-amyloid and its...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $437,250 to the University of California, San Diego (UCSD) from September 2024 to August 2026 to conduct research on the blood-nerve barrier (BNB) in health and diabetic peripheral neuropathy. The key objectives are to leverage single-cell RNA sequencing to: 1) compare gene expression of BNB...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a $207,960 research project at the University of Texas MD Anderson Cancer Center from September 1, 2024 to August 31, 2026. The project aims to investigate the role of tau phosphorylation and insulin dysregulation in diabetic peripheral neuropathy, a condition affecting millions worldwide. The research will employ high...

The Department of the Army Medical Command awarded Duke University a $1,601,314 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through August 2025 to develop monoclonal antibody-based therapeutics for targeting matrix metalloproteinases and diabetic neuropathy. Through support of basic, applied, and advanced biomedical research, the Military Medical Research and Development program aims to transform...

This Project Grant award from the National Science Foundation (CFDA 47.084 - NSF Technology, Innovation, and Partnerships program) provides $275,000 to Islex Therapeutics, LLC to develop antibody therapeutics for the treatment of stage 3 type-1 diabetes (T1D). The key objectives are to demonstrate the efficacy and safety of beta-cell restorative therapies in preclinical studies, which could lead to new treatment options for millions of patients with severe beta-cell loss. The research initiative...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Qrono, Inc. a $306,500 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop QR402, a first-in-class oral nanomedicine targeting dendritic cells to restore immunological tolerance and prevent the onset of Type 1 Diabetes (T1D). The project aims to prepare and characterize enteric-coated nanoparticles containing the AMPK pathway agonist PF-739 (QR402), which preliminary data...

The National Eye Institute (NEI) awarded a $615,979 Project Grant (CFDA 93.867 - Vision Research) to Wayne State University to investigate a promising peptide-based combination therapy for restoring structure and function in the diabetic cornea. The research aims to: 1) establish the therapeutic role of TB4 and VIP as a combination treatment against diabetes-induced corneal complications; and 2) elucidate the DDR-TRP axis, a novel pathway that has yet to be explored in the cornea under...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $4,164,187 in funding to The Regents of the University of California, San Francisco (UCSF) to develop antigen-directed therapies for autoantibody-associated neuroinflammatory diseases. The key objectives of this 5-year award are to: 1) discover autoantibodies directed to cell...